Multiple myeloma: Differential diagnosis and prognosis

Multiple Myeloma and Related Disorders

Volumn , Issue , 2004, Pages 179-199

  San Miguel, Jesús F ^a   García Sanz, Ramón ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22144487079     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (187)

1. Committee of the Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed Guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4:145–58.
2. Durie BGM. Staging and kinetics of multiple myeloma. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA (eds) Neoplastic diseases of the blood, 2nd edn. New York: Churchill Livingstone, 1991:439–51.
3. Greipp PR, Kyle RA. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of unknown undetermined significance and smoldering myeloma. Blood 1983; 62:166–71.
4. Kyle RA. Idiopathic Bence Jones proteinuria: a distinct entity? Am J Med 1973; 65:222.
5. Greipp PR. Advances in diagnosis and management of myeloma. Semin Hematol 1992; 29(Suppl 2):24–45.
6. Lymphoma Tumor Group. Plasma cell disorders. In: British Columbia Cancer Agency (ed.) Cancer Treatment Policies.
7. Ong F, Hermans J, Noordijk EM, Kluin-Nelemans JC. Is the Durie and Salmaon diagnostic classification system for plasma cell discrasias still the best choice? Ann Hematol 1995; 70:19–24.
8. UK Myeloma Forum. Guideline: diagnosis and managements of multiple myeloma. Br J Haematol 2001; 115:522–40.
9. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749–57.
10. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347–9.
11. Dimopoulos MA, Moulopoulos A, Delasalle K, Alexanian R. Solitary plasmacytoma and asymptomatic multiple myeloma. Hematol Oncol Clin North Am 1992; 6:359–69.
12. Paccagnella A, Cartei G, Fosser V, et al. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer Clin Oncol 1983; 19:1345–51.
13. Bladé J, Rozman C, Montserrat E, Cervantes F, Feliu E, Granena A, et al. Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). Eur J Cancer Clin Oncol 1986; 22:1193–7.
14. San Miguel JF, Bladé J, García-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84:36–58.
15. Waldenström J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 1961; 56:211–21.
16. Kyle RA. Monoclonal gammopathies of undetermined significance. Semin Hematol 1989; 26:176–200.
17. Kyle RA. Benign monoclonal gammopathies–after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68:26–36.
18. Haller J. Frequency of abnormal serum immunoglobulins in the aged. Acta Med Scand 1963; 173:737–45.
19. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol 1982; 35:63–8.
20. Foerster J. Plasma cell disorders: General considerations. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (eds) Wintrobe’s clinical hematology, 10th edn. Baltimore, MD: Williams and Wilkins, 1999:2613–30.
21. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564–9.
22. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974; 133:813–18. 23.
23. Baim BJ: Blood cells: a practical guide. Oxford: Blackwell Science, 1995.
24. Bennet JM, Catowsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick H, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 1989; 42:567–84.
25. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987; 83:1062–8.
26. García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Ma J. et al. Primary plasma cell leukemia: clinical, immunophenotypical, DNA ploidy and cytogenetic characteristics. Blood 1999; 93:1032–7.
27. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol 1994; 88:754–9.
28. Chack L, Cox RS, Bostwick DG, et al. Solitary plasmacytoma of bone. Treatment, progression and survival. J Clin Oncol 1987; 5:1811–15.
29. Frassica DAM, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone. Int J Radiat Oncol Biol Phys 1989; 16:43–8.
30. Knowling MA, Harwood AR, Bergsagel DF. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cells tumors of bone. J Clin Oncol 1983; 1:255–62.
31. Bataille R, Sany J. Solitary myeloma: Clinical and prognostic features of a review of 114 cases. Cancer 1981; 48:845–51.
32. Dimopoulos MA, Kiamouris C, Moulopoulos A. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999; 13:1249–57.
33. Witshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) 1976; 55:217–38.
34. Corwin J, Lindberg RD. Solitary plasmacytoma of bones versus extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer 1979; 43:1007–13.
35. Franchi F, Seminara P, Teodori L, Adone G, Bianco P. The non-producer multiple myeloma. report of a case and review of the literature. Blut 1986; 52:281–7.
36. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 7:2900–2.
37. Sahota SS, Garand R, Mahroof R, Smith A, Juge-Morineau N, Stevenson FK, Bataille R. V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Blood 1999; 94:1070–6.
38. García-Sanz R, Montoto S, Torrequebrada A, García de Coca A, Petit J, Sureda A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:1–9.
39. Schambeck CM, Bartl R, Hochtlen-Vollmar W, et al. Characterization of myeloma cells by means of labeling index, bone marrow histology and serum B2-microglobulin. Am J Clin Pathol 1996; 106:64–8.
40. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology – an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91:2501–7.
41. Portero JA, Martin S, González M, San Miguel JF. Cytochemistry in the differential diagnosis of monoclonal gammopathies. Br J Haematol 1985; 60:768–9.
42. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997; 11:71–88.
43. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996; 87:912–18.
44. Kyle RA, Bayrd ED. The monoclonal gammopathies: multiple myeloma and related plasma-cell disorders. Springfield, IL: Charles C. Thomas, 1976.
45. Witzig TE, Gertz M, Lust JA, Kyle RA, O’Fallon W, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88:1780–7.
46. Rawstron AC, Owen RG, Davies FE. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997; 97:46–55.
47. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, Witzig TE. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and active myeloma. Blood 1996; 88:289–96.
48. Witzig TE, Kyle RA, O’Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering multiple myeloma. Br J Haematol 1994; 87:266–72.
49. Kyle RA: Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997; 11:71–88.
50. Brown RD, Joshua DE, Nelson M, Gibson J, Dunn J, MacLennan CM. Serum thymidine kinase as a prognositc indicator for patient with multiple myeloma: results from the MRC (UK) V trial. Br J Hematol 1993; 84:238–44.
51. Back H, Jagenburg R, Rodjer S, Westin J. Serum deoxythymidine kinese: no help in the diagnosis and prognosis of monoclonal gammopathy. Br J Hematol 1993; 84:746–8.
52. Du Villard L, Guiguet M, Casanovas RO, et al. Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol 1995; 89:243–9.
53. San Miguel J, Corrales A, Alberca I, Vicente V, Lopez Borrasca A. Acute phase reactant proteins in differential diagnosis of monoclonal gammopathy. Neoplasma 1983; 30:57–62.
54. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995; 85:765–71.
55. Merlini G, Perfetti V. Gobbi PG, Quaglini S, Franciotta DM, Marinone G, Ascari E. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol 1993; 83:595–601.
56. Schaar CG, Kaiser U, Snijder S, Ong F, Hermans J, Franck PF, et al. Serum interlukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma. Br J Haematol 1999; 107:132–8.
57. Ohtani K, Ninomiya H, Hasegawa Y, Kobayashi T, Kojima H, Nagasawa T, et al. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br J Haematol 1995; 91:116–20.
58. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 1996; 92:370–4.
59. Blade J, Filella X, Montoto S, et al. Clinical relevance of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) serum levels in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 1998; 102:9–14.
60. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992; 6:285–95.
61. Moulopoulos LA, Dimopoulos MA, Smith TL. Weber DM, Delasalle KB, Libshitz HI, et al. Prognostic significance of magnetic resonance imaging in patients in asymptomatic MM. J Clin Oncol 1995; 131:251–6.
62. Laroche M, Assoun J, Sixou L, Attal M. Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myelome-Midi-Pyrenees Group. Clin Exp Rheumatol 1996; 14:171–6.
63. Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, Frija J, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999; 104:723–9.
64. Pecherstorfer M, Seibel M.J, Woitge HW, Horn E, Schuster J, Neuda J, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997; 90:3743–50.
65. Peest D, Deicher H, Feet W, Harms P, Braun HJ, Planker M, et al. Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy–a pilot study of the German Myeloma treatment group (GMTG). Eur J Cancer 1996; 32:2053–7.
66. Nawawi H, Samon D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta 1996; 30:61–77.
67. Bataille R, Delmas PD, Sany J. Serum bone gla-protein (osteocalcin) in multiple myeloma. Cancer 1987; 59:329–34.
68. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum gla-protein in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 1990; 66:167–72.
69. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81:2658–63.
70. Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF: Expression of the CD117 antigen (c-kit) on normal and myelomatous plasma cells. Br J Haematol 1996; 95:489–93.
71. San Miguel JF, Almeida J, Mateo G, Blade J, López-Berges MC, Caballero MD, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002; 99:1853–6.
72. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152:1655–65.
73. Rawstron AC, Fenton JA, Ashcroft J, English A, Jones RA, Richards SJ, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not notmal plasma cells. Blood 2000; 96:3880–6.
74. Mills KH, Cawley JC. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983; 53:271–5.
75. San Miguel JF, Gonzalez M, Gascon A, Moro MJ, Hernandez JM, Ortega F, et al. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1992; 80:305–9.
76. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. Blood 1997; 90:340–5.
77. Tienhaara A, Pelliniemi TT. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Lab Haematol 1994; 16:213–23.
78. San Miguel JF, Garcia-Sanz R, Gonzalez M, Orfao A. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol 1995; 8:735–59.
79. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995; 55:3854–9.
80. Lee W, Han K, Drut RM, Harris CP, Meissner LF. Use of fluorescence in situ hybridizatiion for retrospective detection of anueploidy in multiple myeloma. Genes Chromosomes Cancer 1993; 7:137–43.
81. Tabernero D, San Miguel JF, García-Sanz R, et al. Incidence of chromosome numerical changes in multiple myeloma. Fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 1996; 149:153–61.
82. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915–21.
83. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998; 101:7–11.
84. Konigsberg R, Ackermann J, Kaufmann H, Zojer N, Urbauer E, Kromer E, et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 2000; 14:1975–9.
85. Lloveras E, Sole F, Florensa L, Besses C, Espinet B, Gil M, et al. Contribution of cytogenetics and in situ hybridization to the study of monoclonal gammopathies of undetermined significance. Cancer Genet Cytogenet 2002; 132:25–9.
86. Zandecki M, Lai JL, Genevieve F, Bernardi F, Volle-Remy H, Blanchet O, et al. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood 1997; 90:3682–90.
87. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JL, Daviet A, et al. High incidence of criptic translocations involving the immunoglobulin heavy chain gene in multiple myeloma as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999; 24:9–15.
88. Garcia-Sanz R, Orfao A, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Br J Haematol 1995; 90:106–12.
89. San Miguel JF, Garcia-Sanz R, Gonzalez M, Orfao A. DNA cell content studies in multiple myeloma. Leuk Lymphoma 1996; 23:33–41.
90. Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero MD, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999; 107:121–31.
91. Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80:2326–35.
92. Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but not intraclonal diversity. J Immunol 1995; 155:2487–93.
93. Zaccaria A, Tassinari A, Saglio G, Guerrasio A, Tura S. Immunoglobulin gene rearrangements in human multiple myeloma. Br J Haematol 1989; 73:425–32.
94. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood 1996; 87:746–55.
95. Van Riet Y, Heirman C, Lacor P, De Waele M, Thielemans K, Van Camp B. Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 1989; 73:289–95.
96. Isaksson E, Björkholm M, Holm G, Johansson B, Nilsson B, Mellstedt H, et al. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br J Haematol 1996; 92:71–6.
97. Palumbo AP, Boccadoro M, Battaglio S, Corradini P, Tsichlis PN, Huebner K, et al. Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3 of the myc gene, is rearranged in multiple myelomas. Cancer Res 1990; 50:6478–85.
98. Muller JR, Janz S, Potter M. Differences between Burkitt’s lymphomas and mouse plasmacytomas in the immunoglobulin heavy-chain c-myc recombinations that occur in their chromosomal translocations. Cancer Res 1995; 55:5012–20.
99. Sumegi J, Hedberg T, Bjorkholm M, Godal T, et al. Amplification of the c-myc oncogene in human plasma-cell leukemia. Int J Cancer 1985; 36:367–74.
100. Paulin FE, West MJ, Sullivan NF, Whitney RL, Lyne L, Willis AE, et al. Aberrant translational control of the c-myc gene in multiple myeloma. Oncogene 1996; 13:505–13.
101. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3–21.
102. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93:1393–401.
103. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996; 88:674–80.
104. Athanasiou E, Kaloutsi V, Kotoula V, Hytiroglou P, Kostopoulos I, Zervas C, et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol 2001; 116:535–42.
105. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113:831–7.
106. Hoechtlen-Vollmar W, Menzel G, Bartl R, Lamerz R, Wick M, Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 2000; 109:30–8.
107. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16:260–4.
108. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growthfactor receptor 3 gene. Blood 1997; 90:4062–70.
109. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58:5640–5.
110. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92:3025–34.
111. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996; 88:2699–706.
112. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 1993; 81:2708–15.
113. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 1994; 8:758–67.
114. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86:4250–6.
115. Hernández JM, Gutiérrez NC, Almeida J, et al.: IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. Br J Haematol 1998; 103:163–7.
116. Cigudosa JC, Rao PM, Calasanz MJ, Odero MD. Characterization of non random chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91:3007–14.
117. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91:3366–71.
118. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G, et al. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 1994; 8:1280–4.
119. Juge-Morineau N, Mellerin MP, Francois S, et al. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 1995; 91:664–70.
120. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 1997; 90:1982–92.
121. Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Sugimoto Y, et al. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res 1997; 3:2173–9.
122. Gonzalez M, Mateos MV, Garcia-Sanz R, Balanzategui A, Lopez-Perez R, Chillon MC, et al. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia 2000; 14:183–7.
123. Kim DK, Cho ES, Lee SJ, Um HD. Constitutive hyperexpression of p21(WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas. Biochem Biophys Res Commun 2001; 289:34–8.
124. Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001; 98:244–6.
125. Mateos MV, Garcia-Sanz R, López-Pérez R, Balanzategui A, González MI, Fernández-Calvo J, et al. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2001; 2:146–9.
126. Kyle RA. Why better prognostic factors for multiple myeloma are needed? Blood 1994; 83:1713–16.
127. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells 1995; 13:56–63.
128. San Miguel JF. Overview of prognostic factors in multiple myeloma. Cancer Res Ther Control 1998; 6:97–9.
129. Turesson I. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999; 106:1005–12.
130. Bladé J. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93:345–51.
131. Modiano MR, Villar-Werstler P, Crowley J, Salmon SE. Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol 1996; 14:974–7.
132. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98:23–8.
133. Österborg A, Nilsson B, Björkholm M. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Immunol 1990; 45:153–7.
134. García-Sanz R, González M, Orfao A, Moro MJ, Hernandez JM, Borrego D, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 1996; 93:81–8.
135. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997; 11:1312–17.
136. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(-)CD28(-) compartment. Blood 2001; 98:2817–27.
137. Bartl R, Frisch B, Burkhardt R, Fateh-Moghadam A, Mahl G, Gierster P, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol 1982; 51:361–75.
138. Greipp PR. Advances in the diagnosis and management of myeloma. Semin Hematol 1992; 92 (Suppl 2):24–45.
139. Saeed SM, Stock-Novack D, Pohlod R, Crowley J, Salmon SE. Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood 1991; 78:3281–7.
140. San Miguel JF, González M, Gascón A, et al. Immunophenotype heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Br J Haematol 1991; 77:185–90.
141. Omede P, Boccadoro M, Fusaro A, Gallone G, Pileri A. Multiple myeloma: ‘early’ plasma cell phenotype identifies patients with aggresive biological and clinical characteristics. Br J Haematol 1993; 85:504–13.
142. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84:2597–603.
143. Pellat-Deceunynck C, Barille S, Puthier D, Rapp MJ, Harousseau JL, Bataille R, et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumour spreading and immortalization. Cancer Res 1995; 55:3647–53.
144. San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85:448–55.
145. Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 1998; 4:1521–6.
146. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000; 95:388–92.
147. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15:2659–66.
148. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95:1925–30.
149. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001; 15:981–6.
150. Fonseca R, Harrington D, Blood E, Rue M, Oken MM, Dewald GW, et al. A molecular clasiffication of multiple myeloma based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis. Blood 2001; 98:733a.
151. Worel N, Greinix H, Ackermann J, Kaufmann H, Urbauer E, Hocker P, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 2001; 80:345–8.
152. Segeren C, Beverloo B, Poddighe J, Slater R, van der Holt B, Steijaert M, et al. Abnormal chromosomes 1p/q and 13/13q are adverse prognostic factors for the outcome of upfront high-dose therapy in patients with multiple myeloma. Blood 2002; 98:159a.
153. Skopelitou A, Hadjiyannakis M, Tsenga A, Theocharis S, Alexopoulou V, Kittas C, et al. Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases. Anticancer Res 1993; 13:1091–5.
154. Drach J. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802–9.
155. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81:490–5.
156. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996; 10:1741–50.
157. Gieseler F, Nussler V. Cellular resistance mechanisms with impact on the therapy of multiple myeloma. Leukemia 1997; 11(Suppl 5):S1–S4.
158. Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, et al. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91:1029–36.
159. Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81:3382–7.
160. Orfao A, Garcia-Sanz R, Lopez-Berges MC, Belen VM, Gonzalez M, Caballero MD, et al. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994; 17:332–9.
161. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol 1996; 94:76–81.
162. Hansen OP, Jessen B, Videbaek A. Prognosis of myelomatosis on treatment with prednisone and cytostatics. Scand J Haematol 1974; 10:282–90.
163. Boccadoro M, Pileri A. Cell kinetics of multiple myeloma. Hematol Pathol 1987; 1:137–42.
164. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842–54.
165. San Miguel JF, Sanchez I, Gonzalez M. Prognostic factors and classification in multiple myeloma. Br J Cancer 1989; 59:113–18.
166. Cuzick J, De Stavola BL, Cooper EH. Long-term prognostic value of serum B-2μ microglobulin in myelomatosis. Br J Haematol 1990; 75:506–10.
167. Garewal H, Durie BGM, Kyle RA, Finley P, Bower B, Serokman R. Serum B2 microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984; 2:51–7.
168. Bataille R, Greiner J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis and treatment: a prospective study of 160 patients. Blood 1984; 63: 468–76.
169. Boccadoro M, Omede P, Frieri R. Multiple Myeloma: beta-2-microglobulin is not a useful follow-up parameter. Acta Haematol 1989; 82:122–5.
170. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008–11.
171. Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 1997; 97:191–5.
172. Pulkki K, Pelliniemi R.T, Rajamaki A, et al.: Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996; 92:370–4.
173. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80:733–7.
174. Facon T, Menard JF, Michaux JL, Euller-Ziegler L, Bernard JF, Grosbois B, et al. Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d’Etudes et de Recherche sur le Myelome (GERM). Am J Hematol 1995; 48:71–5.
175. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997; 97:810–14.
176. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995; 32:31–44.
177. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995; 13 (Suppl 2):140–6.
178. Shaughnessy J Jr, Barlogie B, McCoy JPJ, Sawyer J, Fassas A, Zangari M, et al. Early relapse after Total Therapy II for multiple myeloma is significantly associated with cytogenetic abnormalities of chromosome 13 (CA13) but not interphase FISH-del 13 or plasma cell labeling index (PCLI). Blood 2001; 98:734a.
179. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19:337–42.
180. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26:979–83.
181. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55–65.
182. Lahuerta JJ, de la Serna J, Blade J, Grande C, Alegre A, Vazquez L, et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109:438–46.
183. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27:1037–43.
184. Tricot G, Spencer A, Desikan KR, Badros A, Zangari M, Toor A, et al. Predicting long term (≥5 YR) event-free survival (EFS) in multiple myeloma following tandem autotransplants (TT). Blood 2002; 98:2787–93.
185. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88:2787–93.
186. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312–22.
187. Greipp Ph, San Miguel JF, Fonsea R, Avet-Loiseau H, Jacobson JL, Rasmussen E, et al. On behalf of the International Myeloma Working Group plus Cancer Research and Biostatistics (CRAB). Development of an international prognostic index (IPI) for myeloma: report of the International Myeloma Working Group at the IXth International Workshop on Multiple Myeloma, Salamanca, Spain. May 23–27, 2003. Hematol J 2003; 4(Suppl 1):S42.